Eltrombopag is a small molecule, non-peptide thrombopoietin receptor (TPO-R) agonist and has recently been approved for the treatment of thrombocytopenia in patients with chronic ITP.
Introduction
Survival in acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS) has remained poor despite recent efforts to treat patients with novel therapeutic regimens. [1] [2] [3] [4] In addition, complications secondary to thrombocytopenia and bleeding occur frequently in AML and MDS, leading to significant morbidity and mortality. 5, 6 Given the median age of patients with AML is close to 70 years, novel anti-leukemia agents, with limited bone marrow toxicity, are needed to improve outcomes.
Eltrombopag (EP) is an oral, non-peptide, small molecule thrombopoietin receptor (TPO-R)
agonist which has proven efficacy in treating chronic immune thrombocytopenic purpura (ITP) and hepatitis C related thrombocytopenia. 7, 8 Despite concerns that some leukemia blast cells express the TPO-R, we and others have previously reported that EP does not stimulate leukemia or MDS cell growth, but may rather lead to a modest inhibition, while continuing to stimulate normal megakaryopoiesis in bone marrow samples of patients with AML or MDS.
9,10
One study utilizing a close chemical derivative of eltrombopag indeed found a toxic effect on myeloid leukemia cells, suggesting that the entire substance class including eltrombopag itself may possess anti-leukemic activity. 11 Cell line studies further suggested that the growth inhibitory effect of eltrombopag is not related to expression levels of the TPO-R. 12 However, this hypothesis has not yet been formally tested, and the mechanism through which EP exerts its potential anti-leukemic effect is not known. Of note, the concentrations at which EP inhibits leukemia cell proliferation in vitro are clinically achievable with few side effects, and have led to desirable increases in circulating platelet counts in healthy volunteers.
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In the current study we examined cellular and molecular mechanisms by which EP exerts its anti-leukemic effect, utilizing both in vitro and in vivo models of acute myeloid leukemia. We
show that EP has a profound leukemia-inhibitory effect independent of the TPO-R in vitro and in
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Material and Methods

Reagents
Eltrombopag (SB-497115) was dissolved as a 1mg/mL stock solution in distilled water and stored light protected at room temperature for up to 2 weeks. Salicylaldehyde isonicotinoyl hydrazine (SIH) was a generous gift of Dr. Katherine Franz (Duke University). Deferoxamine Mesylate (DFO), Ferrous Ammonium Citrate, N-acetyl-L-cysteine (NAC) were obtained from Sigma Aldrich. Recombinant human thrombopoietin (TPO) and recombinant mouse TPO were obtained from Invitrogen.
Cell Culture
HL60, U937, and HS5 cells were cultured in RPMI (CellGro) with 10% fetal bovine serum (Gemini) (FBS) at 37 o . URE murine AML cells were obtained from PU.1-knockdown mice with targeted disruption of the distal enhancer (URE) -14kb upstream of the PU.1 gene. 14,15 URE cells were maintained in M5300 media (Stem Cell Technologies) supplemented with 10% heatinactivated FBS, 15% supernatant of WEHI-3B culture medium, 15% supernatant of BHK culture medium and penicillin/streptomycin. 
Cell proliferation assays
Intracellular iron detection assays
HL60, URE, and U937 cells were harvested and resuspended in RPMI supplemented with 10%
FBS and 250 nM calcein-AM (Invitrogen) and were incubated for 5 minutes at 37°C.Cells were washed and resuspended in pre-warmed culture media. Cells were subsequently left untreated, or were treated with EP, TPO, SIH, or DFO for 1 or 4 hours. Intracellular calcein fluorescence was measured by flow cytometry on a BD FACSAria II instrument (BD Bioscience) and mean fluorescence was calculated by Diva software (BD Bioscience). Transferrin receptor expression was measured by FACS analysis utilizing antibodies against human CD71 (11071973; eBioscience) and murine CD71 (557416; BD Pharmigen).
Cell cycle assays
The Click-iT TM EdU Flow Cytometry Assay system (Invitrogen) was used following the manufacturer's instructions. Briefly, after culture of cells with EdU (10μM) for 2 hours, cells were fixed by 4% paraformaldehyde, treated with saponin containing buffer, and then incubated with
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Cell Division Assays
The Cell Tracker Orange Assay (Invitrogen) was used following the manufacturer's instructions.
Briefly, cells were labeled with cell tracker at a concentration of 10uM via incubation at 37 o for 30 minutes. Cells were washed, maintained in culture and analyzed by fluorescence activated cell sorting FACS every 24 hours.
Differentiation Assays
Cell differentiation was assessed 72 hours after treatment. Morphology was examined after Diff Quik (IMEB) staining as well as FACS analysis utilizing antibodies directed against CD11b (555389; BD Pharmigen) and CD14 (MHCD1406; Invitrogen) for human cell lines, and CD11b (12011282; eBioscience) for murine cell lines.
Intracellular Reactive Oxygen Species (ROS) Assays
FACS analysis was used to determine the level of intracellular ROS in response to various treatments. Briefly, HL60, URE, and U937 cells were loaded with 5uM H2DCFDA (Invitrogen) for 30 minutes, washed and evaluated by flow cytometry.
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In vivo leukemia models
All animal experiments were performed in compliance with institutional guidelines and approved by the Animal Institute Committee of the Albert Einstein College of Medicine (protocol #20110102).
NOD-SCID IL2Rγ null (NSG) mice were sub-lethally irradiated (200 rad) and were intravenously inoculated with 1x10 6 URE cells. At day +3 mice were divided into 3 groups. The first group received untreated drinking water, the second group received drinking water with 0.4mg/mL EP, and the third group received 1.0mg/mL EP in the drinking water. The untreated and treated water was changed every 3 days. Mice were monitored for signs of leukemia and their bone marrow and spleens were harvested at death. For experiments with human leukemia cells, NSG mice were sub-lethally irradiated (200 rad) and were intravenously inoculated with 1x10 7 HL60
cells. At day +3 mice were divided into 3 groups. The first group received untreated drinking water, the second group received drinking water with 1.0mg/ml EP, and the third group received 3.0mg/ml EP. The untreated and treated water was changed twice every week. Mice were monitored, assessed for engraftment, and their bone marrow and spleens were harvested at death. Engraftment was assessed by FACS analysis utilizing antibodies directed against murine CD45.1 (12045383; EBioscience) and human CD15 (11015973; EBioscience).
Microarray experiments and analysis
RNA was extracted from HL60 cells after 12 hrs and 36 hrs of treatment with EP, TPO, or without treatment using Trizol Reagant (Invitrogen). After evaluation of the quality of RNA with an Agilent2100 Bioanalyzer, RNA was labeled with the GeneChip WT terminal labeling kit (Affymetrix), labeled cRNA of each individual sample was hybridized to Affymetrix Humane Gene 1.0ST microarrays (Affymetrix), stained, and scanned by GeneChip Scanner 3000 7G
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Statistical Analysis
Results are reported as the mean plus or minus standard deviation. Student t test was utilized to determine statistical significance in the in vitro experiments. P value less than 0.05 was considered statistically significant. For in vivo experiments, log-rank test was utilized to determine statistical significance of observed differences in overall survival.
Results
Eltrombopag leads to a decreased cell division rate and a block in G1 phase of cell cycle in human and murine leukemia cells
We evaluated the dose of EP required to inhibit HL60 cell (human) and URE cell (murine) proliferation. A murine cell line was evaluated in all experiments because EP is highly speciesspecific and does not activate the TPO receptor pathway in murine cells.
16 HL60 cells and URE cells were incubated with increasing concentrations of EP for 72 hours. Manual cell counts and MTS assays were performed every 24 hours. EP inhibits HL60 cells and URE cells ( Figure 1A) in a dose dependent manner at in vitro concentrations that are achievable in vivo. 13, 17 To evaluate the effect of EP on the rate of cell division, HL60 cells and URE cells were labeled with Cell Tracker Orange (Invitrogen) and cells were analyzed by FACS every 24 hours for 3 days.
EP slows cell division rate by 48 hours of treatment in both human HL60 cells and murine URE cells ( Figure 1B i-iv). Figure 1C i-ii). Consistent with these findings, gene expression analysis by microarray of HL60 cells performed 36 hours after EP treatment showed the down-regulation of genes important for the transition from G1 to S phase compared to untreated cells. ( Figure 1D , and supplemental Figure 1A -B). To confirm EP's effect on cell division and cell cycling is consistent in other human cell lines, EP was tested in U937 cells. Supporting our findings, EP slowed cell division and led to a block in the cell cycle in G1 phase in U937 cells (supplemental Figure 2 ).
Eltrombopag induces differentiation of leukemia cell lines
Next we tested EP's effect on differentiation. HL60 cells were incubated without EP, with 5 ug/ml of EP, or with thrombopoietin for 72 hours and cytospins were performed followed by Diff Quik staining. HL60 cells treated with Eltrombopag showed clear signs of differentiation, significant changes in the organization of the nuclear contents, and an increase in the cytoplasm/nucleus ratio, while thrombopoietin did not induce significant morphologic changes ( Figure 2A ). FACS analysis confirmed EP differentiates HL60 cells with significant increases in mature myeloid markers, CD11b (2.98 fold, p<0.001) and CD14 (1.61 fold, p=0.003) ( Figure 2B i-iv).
We evaluated whether EP induces differentiation of another human cell line (U937 cells), and murine URE leukemia cells. At 72 hours after EP treatment, both cell lines showed significant For personal use only. on April 19, 2017. by guest www.bloodjournal.org1 0 differentiation-associated morphologic changes with increased cell size, and the formation of vacuoles within the cytoplasm of U937 cells ( Figure 2C ). EP caused an increase in CD11b (2.25 fold, p=0.007) consistent with a pre-macrophage state in U937 cells and also cause an increase in CD11b in URE cells (1.15 fold, p=0.04) ( Figure 2D ).
Eltrombopag reduces intracellular iron in leukemia cells
Upon treatment with EP, gene expression arrays of HL60 cells showed an overexpression of the transferrin receptor (CD71) which is required for iron transport. This increase in CD71 expression was validated by FACS (see also Figure 3D ). Given the overexpression of CD71 and the knowledge that EP shares structural similarities to well-described metal chelators, we hypothesized that some of the observed cell biological effects of EP could be mediated by reduction of intracellular iron (supplemental Figure 3) Figure 3A ). After 4 hours of treatment, concentrations as low as 1ug/ml of EP increased the labile intracellular iron pool by 5.12% +/-0.79% ( Figure 3A) . Interestingly, treatment with 10ug/ml of EP (pharmacologically achievable concentration) resulted in even greater intracellular iron reduction (23.5%, p=0.003) than the highly potent chelator SIH ( Figure 1 1 3A). To determine whether reduction of intracellular iron is a consistent feature of EP across multiple leukemia cell lines, 5 additional cell lines were tested (4 human, 1 murine). All cell lines displayed significant intracellular iron reduction after treatment with 5ug/ml of EP ( Figure 3B ).
Consistent with the finding that EP chelates intracellular iron, gene expression 12 and 36 hours after EP treatment showed the cells are responding to iron depletion by up-regulating the transferrin receptor (CD71) and down-regulating the ferritin light and heavy chains ( Figure 3C ).
The transferrin receptor transports iron intra-cellularly while ferritin stores iron when it is in excess. In addition, we found CD71 surface antigen in both HL60 and URE cells to be overexpressed as early as 24 hours after treatment with EP ( Figure 3D ). To show CD71
expression is increased in response to EP induced iron deprivation, HL60 cells were pre-loaded with iron utilizing ferrous ammonium citrate (FAC) and subsequently treated with EP. Consistent with our hypothesis, cells loaded with iron and treated with EP showed decreased expression of CD71 compared to cells treated only with EP ( Figure 3D ). To assess whether iron depletion is characteristic of other TPO agonists, we assessed the ability of a peptidyl TPO agonist to deplete intracellular iron. Four hours after treatment with high dose Romiplostim no significant reduction in iron was observed (supplemental Figure 4) .
Inhibition of leukemia cell proliferation and induction of differentiation by EP is mediated by a reduction of intracellular iron
The mechanism by which EP inhibits leukemia cell growth has not been well understood. Given that EP leads to a reduction of intracellular iron and iron chelators have been shown to have anti-proliferative effects in myeloid leukemia cells, we tested whether EP's anti-leukemic effect is secondary to its ability to deplete intra-cellular iron. We performed iron rescue experiments by pre-loading HL60 cells with 500ug/ml FAC for 24 hours, which resulted in a 9.76% +/-2.10%
For personal use only. on April 19, 2017. by guest www.bloodjournal.org From increase in intracellular iron. HL60 cells were subsequently left untreated (control), treated with EP, TPO (negative control), or DFO (positive control). Pre-loading cells with iron resulted in a rescue from the anti-proliferative effects of EP as determined by cell count (95% growth increase, p<0.01) and MTS assay after 72 hours ( Figure 4A ). We made very similar observations in murine leukemia cells as iron-loaded URE cells were also rescued from the antiproliferative effects of EP (84% growth increase, p<0.01) ( Figure 4B ).
To assess whether the inhibition of cell division rate by EP could also be rescued by increasing the intracellular iron content of HL60 cells, FAC was preloaded into cells for 24 hours followed Knowing that ROS levels vary with intracellular iron levels and that iron chelators have been shown to induce ROS formation, we investigated whether EP also induces ROS. 20 We used H2DCFDA (Invitrogen) with flow cytometry to assess intracellular ROS levels. HL60, URE, and U937 cells were treated with 5ug/ml EP for 1 hour and were subsequently incubated with 5uM
H2DCFDA. All cell lines showed significant increases in ROS formation after only one hour of treatment (supplemental Figure 5A -B). In order to determine whether ROS generation was involved in EP induced differentiation of HL60 cells, we incubated the cells with the anti-oxidant N-acetyl-L-cysteine during EP treatment, which resulted in a 92% rescue of ROS activity (supplemental Figure 5C ). CD11b and CD14 expression (-22 Figure 5D ).
Eltrombopag prolongs survival in mouse models of leukemia
Given the in vitro anti-leukemic effect of EP, we next evaluated the effect of EP in murine transplantation models of leukemia. Ten million HL60 cells were intravenously injected into NSG mice via the tail vein and mice were treated starting day +3 with 1.0mg/ml EP in the drinking water or untreated drinking water. Bone marrow aspirations at day +21 showed that mice treated with EP had significantly lower donor cell chimersim (5.6% vs. 21.1%, p=0.03) ( Figure 5Ai ). EP treatment significantly improved survival in these mice (p=0.01) ( Figure 5Aii) and engrafted leukemia cells in EP-treated mice showed increased CD11b and CD14 expression (supplemental Figure 6) , consistent with our observations in vitro. Given that high doses of EP have been well tolerated in humans we assessed the effect of higher dose EP in our HL60 leukemia mouse model. Mice treated with 3.0mg/ml EP in the drinking water showed significantly increased median survival compared with control mice and mice treated with 1.0mg/ml EP, respectively (p<0.01) (Figure 5Aii ).
We next assessed the effect of EP in NSG mice transplanted with URE leukemia cells. One million URE cells were intravenously injected via the tail vein in NSG mice. Mice were then treated starting day +3 with 0.4mg/ml or 1.0mg/ml EP in the drinking water, or untreated drinking water. We have previously shown that treatment with 0.3mg/ml EP in the drinking water results in EP serum levels greater than 2ug/mL. 10 EP showed a dose dependent, statistically significant (0.4mg/ml EP p=0.005, 1.0mg/ml EP p=0.002) effect on the survival of mice with URE cell leukemia ( Figure 5B ), once again demonstrating the leukemia-inhibitory effect of EP in vivo.
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We assessed the effect of EP given in combination with standard AML chemotherapeutic agents. HL60 cells were incubated with EP with or without Cytarabine or Doxorubicin. Manual cell counts at 72hrs showed the addition of EP significantly enhanced the anti-proliferative effects of Cytarabine and Doxorubicin, respectively (p=0.002; and p=0.005) (Figure 5Ci -ii).
Finally, given that stromal cells in multiply transfused patients are often iron overloaded and may mitigate the anti-leukemic effect of EP, we performed co-incubation experiments in vitro.
Human HS5 stromal cells, were preloaded with iron or mock-treated for 72 hours and then coincubated with HL60 cells with or without EP treatment. Neither untreated nor iron overloaded stromal cells alleviated the inhibitory effect of EP on HL60 cell proliferation (supplemental Figure   7 ).
Discussion
In this study we report the non-peptide, small molecule thrombopoietin receptor agonist eltrombopag inhibits leukemia cell growth by depletion of intracellular iron. Eltrombopag is currently being investigated in clinical trials for treatment for thrombocytopenia in patients with MDS and the new discovery that EP reduces intracellular iron provides support that eltrombopag may be a promising adjuvant agent for patients with AML and MDS for a number of reasons. First, the majority of patients with AML and MDS are over the age of 60 and thus many patients are not able to tolerate intensive chemotherapy and transplant conditioning regimens. [4] [5] [6] Additionally, many patients with AML and MDS are transfusion dependent and suffer from iron overload. Finally, many patients endure significant morbidity and mortality related to thrombocytopenic bleeding in MDS. An agent such as Eltrombopag that has an anti-leukemic effect and does not induce thrombocytopenia, but rather stimulates megakaryopoeisis and
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Our in vitro studies demonstrate that EP inhibits leukemia cell growth through induction of differentiation, as well as slowed cell division mediated by inhibition of cell cycle transition from G1 to S phase. These observations are similar to and consistent with prior literature describing the anti-leukemic effects of known iron chelators and differentiating agents. [20] [21] [22] [23] [24] [25] [26] Studies show that iron chelators have anti-cancer effects in a variety of malignancies including breast cancer, and melanoma, as shown in patients as well as solid tumor xenograft models. 25, 27, 28 It is unclear which exact molecular pathways are mediating the anti-leukemic effects upon EP-induced reduction of intracellular iron. Our data suggest that down-regulation of cell cycle-promoting genes and/or an increase of ROS may play a role. However, near complete rescue of ROS with NAC resulted only in a partial rescue from the differentiating effects of EP, suggesting that ROS is not the sole pathway mediating differentiation. Further mechanistic studies will be required to understand the precise molecular and functional sequelae of EP treatment in leukemia cells. It will also be important to further understand how EP interacts with traditional chemotherapy agents, as clinically it would likely be given in conjunction with other cytotoxic therapies. Given EP's ability to reduce intracellular iron and inhibit growth in leukemia cells, it also seems promising to evaluate the anti-proliferative or differentiating effects of EP in other malignancies.
Previous studies have shown the TPO receptor is present on a significant percentage of AML cells, and have demonstrated TPO may stimulate blast cells expressing TPO-R. [29] [30] [31] Recent studies have postulated the anti-leukemic effect of EP is independent of the TPO-R pathway by demonstrating the effect of EP in leukemia and lymphoma cells lines was not related to the level of TPO-R expression. 12 In addition, a peptibody that stimulates platelet production through the TPO-R may stimulate blast production and the transformation form MDS to AML in patients with low-risk MDS. 32 We demonstrate EP's ability to reduce intracellular iron is not a mechanism 1 6
shared by the peptibody TPO-R agonist (supplemental Figure 3) . Here, we show for the first time, the anti-leukemic effect of EP is not related to the TPO-R pathway. It has been previously shown that EP interacts with the transmembrane domain of the TPO-R, and that this interaction and consecutive TPO-R downstream signaling is highly species-specific and only occurs in humans and primates, but not in murine cells. 16 Our finding of growth inhibition and differentiation of murine leukemia by EP in vitro and in vivo demonstrates that these effects are TPO-R-independent.
The design of small molecule, non-peptidyl thrombopoietin mimics was originally based on the premise these molecules have three main features: a lipohilic end, an acidic end, and a chelator backbone (supplemental Figure 2) . 33, 34 The structure of Eltrombopag has these three elements and supports EP's ability to reduce intracelullar iron and potentially other polyvalent cations. 35, 36 Given that Eltrombopag has a chelator backbone that is not iron specific, it is likely that EP chelates other polyvalent cations such as zinc and copper. A recent double blind, placebo controlled randomized dose escalation study showed maximum serum concentrations of EP of over 20ug/ml are clinically achievable with minimal toxicity.
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These levels are equal or higher than the levels at which EP reduces intracellular iron and exhibits potent anti-leukemia effects in our in-vitro experiments and in-vivo mouse models.
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Interestingly, bone marrow suppression and anemia has not been reported in patients receiving eltrombopag. 7, 8, 17 This supports the selective anti-cancer effect of iron chelators and the ability of normal hematopoietic cells to better tolerate iron depletion compared to malignant cells.
7
The properties of eltrombopag may prove important as both an adjuvant anti-cancer therapy, as well as a supportive care agent, potentially improving platelet counts and platelet recovery in patient's receiving marrow suppressive treatments as well as reducing excess iron in multiplytransfused patients. 39 Our study provides the basis to further study EP in MDS and AML patients as well as to consider exploring its effectiveness in other cancers.
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